Viridian Therapeutics, Inc. (VRDN) Tops Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts VRDN Hot Sheet
Join SI Premium – FREE
Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q1 EPS of ($0.87), $0.11 better than the analyst estimate of ($0.98). Revenue for the quarter came in at $70 thousand versus the consensus estimate of $52.09 thousand.
For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI-powered cyber threats light a fire under cybersecurity stocks
- Tompkins Financial (TMP) Tops Q3 EPS by 5c
- UBS Reiterates Buy Rating on Expeditors Int'l (EXPD)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
